Background: The antineoplastic drug 5-fluoruracil (5-FU) is a pirimidine analog, which frequently induces potentially fatal diarrhea and mucositis. Cannabinoids reduce gastrointestinal motility and secretion and might prevent 5-FU-induced gut adverse effects. Here, we asked whether cannabinoids may prevent diarrhea and mucositis induced by 5-FU in the rat. ). Gastrointestinal motor function was radiographically studied after barium contrast intragastric administration on experimental days 1 and 4. Structural alterations of the stomach, small intestine and colon were histologically studied on day 4. PAS staining and immunohistochemistry for Ki67, chromogranin A and CD163 were used to detect secretory, proliferating, and endocrine cells, and activated macrophages respectively.
3
Unidad Asociada I+D+i al Instituto de Química Médica, IQM (CSIC), Madrid, Spain infection, and hemorrhage leading to impaired quality of life and higher time and cost of hospitalization. 4 Moreover, patients may require reductions in dosing or may no longer be able to continue cancer therapy in severe cases. 5 5-fluorouracil (5-FU), a pyrimidine analog frequently used to treat breast or colorectal cancer (CRC), induces mucositis in 50-80% of patients, resulting in abdominal bloating and vomiting and diarrhea. 4, 6 Mucositis is probably the main factor involved in chemotherapyinduced diarrhea (CID), characterized by an imbalance between absorption and secretion in the gut. 6, 7 CID is potentially fatal due to dehydration (which may compromise cardiovascular and renal function and trigger electrolyte disorders), and rupture of the intestinal barrier (which may cause infection and sepsis). 7, 8 CID affects 25% of CRC patients receiving 5-FU as single agent (6-13% with severe diarrhea, grades 3/4) and can be severe in up to 40% receiving combination chemotherapy. [9] [10] [11] Mucositis and its associated diarrhea management are still limited to analgesics, antibiotics, and antidiarrheal and mucosal protective agents. However, these are only palliative and frequently non-effective. 10, [12] [13] [14] Thus, mucositis and CID remain an unmet medical problem, requiring evaluation of new treatment options.
Cannabinoids exert potent effects on the gastrointestinal tract. 15, 16 Cannabinoid agonists are empirically used in the clinic to prevent chemotherapy-induced nausea and vomiting (CINV) and these effects have been confirmed and characterized in different animal models. [15] [16] [17] Interestingly, however, heavy cannabis smokers develop hyperemesis, 18 which might be due to gastric dysmotility. In fact, high (centrally acting) doses of cannabinoids intensely delayed gastric emptying after acute, daily, and intermittent administration in the rat without tolerance development. [19] [20] [21] Cannabinoids also reduce diarrhea associated to a number of conditions. 22, 23 In experimental animals, non-selective, CB 1 and CB 2 selective agonists prevented diarrhea induced by different stimulants. [24] [25] [26] Activation of both CB 1 and CB 2 cannabinoid receptors might be useful against CID, due to their respective antimotility/antisecretory, and anti-inflammatory effects. 15, 27 To our knowledge, cannabinoid agonists (exogenously administered) have never been tested in animal models of 5-FU-induced diarrhea/mucositis. Therefore, our aims were: to characterize the effects of 5-FU on gastrointestinal motility in the rat using radiographic techniques (which 
| MATERIALSANDMETHODS
The experiments were designed and performed in accordance with the European and Spanish legislation on care and use of experimental animals (2010/63/UE for animal experiments; Real Decreto 53/2013), and were approved by the Ethic Committee at Universidad Rey Juan Carlos (URJC).
| Animalsandtreatment
Male Wistar rats (250-300 g at the beginning of the experiment) were Throughout experiment (days 1-4) bodyweight, food intake, water intake, and signs of general toxicity, were recorded. Gut motility studies were performed on days 1 and 4 in one group of animals (n=32).
In a parallel group of animals that received the same treatments and whose bodyweight, and food and water intake were similarly evaluated (n=26), samples were obtained from the small intestine to perform histological studies. Details of gut motility and histological studies are described below.
| Scheduleof5-FUandcannabinoid administration
In pilot experiments, we used a single dose of 150 mg kg −1 by the ip route. 29, 30 However, 4 days after administration, we could not see any radiographic sign of diarrhea, upon which to test the possible antidiarrheal effect of cannabinoids. In fact, this is probably a very low dose compared to that used in humans (5-FU in the standard FOLFIRI regimen for CRC is dosed at 2400 mg m −2 , and it has been calculated that
KeyPoints
• Mucositis and diarrhea are debilitating side effects associated to cancer chemotherapy, but still lacking optimal clinical management. New therapeutic approaches are required.
• In the presence of histologically demonstrated mucositis, the antineoplastic drug 5-fluorouracil delayed gastric emptying and induced diarrhea. The cannabinoid agonist WIN 55,212-2 at a low, non-psychoactive dose partially reduced diarrhea, but not mucositis.
• This is the first experimental study showing that cannabinoids may have a role to counteract chemotherapy-induced diarrhea.
the dose of 400 mg kg −1 in rats would correspond to 2222 mg m −2 in patients 31, 32 ). Therefore, we decided to administer a second dose on the following day (cumulative dose of 300 mg kg −1 , similar to others intravenous route, 33 oral route, 34 ). This schedule was effective to induce diarrhea radiographically observable and was then adopted for our study, although we assume that the 5-FU dosage is probably still lower than that used in clinical chemotherapy.
Regarding WIN, the dose chosen (0.5 mg kg −1 ) did not induce significant central effects, except for slight analgesia, did not significantly alter gastric motility either in acute or repeated administration for 14 days, but slightly delayed small intestinal transit, 19, 20 which could be beneficial for preventing 5-FU-diarrhea. Taking into account these previous data from our own laboratory, we performed an invasive test using the charcoal method, 35 which confirmed that this dose is effective to slightly but significantly decrease gastrointestinal motor function in naïve animals (see Fig. S2 for methodological details and results of this pilot test). This dose was used thereafter for our study.
| Gutmotilityexperiments
Radiographic techniques were applied in order to non-invasively analyze alterations in gastrointestinal motility induced by 5-FU and the cannabinoid. X-ray shots was adjusted to 0.02 seconds and focus distance was manually fixed to 50±1 cm. Immobilization of the rats in prone position was achieved by placing them inside adjustable hand-made transparent plastic tubes, so that they could not move. Habituation to the recording chamber prior to commencement of the study did not significantly alter gastrointestinal motility. 28 To further reduce stress, rats were released immediately after each shot (immobilization lasted for less than 2 minutes). X-rays were recorded at different times (immediately and 1, 2, 4, 6, and 8 hours: T0-T8) after administration of the contrast medium. While X-ray shooting, the qualified investigator remained, behind a lead screen, at least 2 m away from the X-ray source.
Analysis of the radiographs was performed by a trained investigator blind to the drug administered. Alterations in gut motility were semi-quantitatively determined from the images by assigning a compounded value to each gastrointestinal region considering the following parameters: percentage of the region filled with contrast (0-4); intensity of contrast (0-4); homogeneity of contrast (0-2); and sharpness of the gut region profile (0-2). Each of these parameters was scored and a sum (0-12 points) was made. The X-ray images were also morphometrically analyzed with the aid of an image analysis system (ImageJ 1.38 for Windows, National Institute of Health, USA, free software: http://rsb.info.nih.gov/ij/) and the alterations in size of stomach and caecum were studied.
Finally, severity of diarrhea was specifically assessed applying the following score to the appearance of the colorectum on the X-rays:
0-no diarrhea; 1-mild diarrhea (both liquid and fecal pellets); 2-severe diarrhea (only liquid). In addition, since some barium contrast from day 1 radiographic analysis could still be seen in the gut on day 4 at T0, we analyzed the presence of these "shadows" for the different experimental groups. For this, a further score was applied to each intestinal region on each T0 (day 4) X-ray: 0-no barium content remaining from day 1; 1-barium content remaining from day 1. Afterwards, the values obtained for the different intestinal regions were summed to give the final value (0-3 points) of the intestinal "shadows" on the X-ray.
| Histopathologicalanalysisof gastrointestinalregions
On day 4, samples were obtained from the stomach (fundus and body),
terminal ileum (at least 10 cm oral to the ileocaecal junction) and colon The experimenter was blind to the treatment received by the rat from which the sample under analysis was obtained.
Histological damage of the ileum was evaluated in sections stained with HE using criteria adapted from Galeazzi et al. 36 A numerical score of 0-9 was assigned to each section considering general loss of mucosal architecture (graded 0-3, absent to severe), extent of inflammatory cell infiltrate (graded 0-3, absent to transmural), crypt abscess formation (0-1, absent or present), goblet cell depletion (0-1, absent or present), and muscular layer thickness (0-1, normal to reduced). The number of damaged villi, inflammatory infiltrates per linear centimeter of intestine and thickness of both muscle layers were also measured.
The number of goblet cells per villi was counted after PAS staining.
Submucosa thickness was measured after staining with Van Gieson to detect collagen fibers. The colon was evaluated according to Saccani et al. 37 The numerical score in this case was 0-13 considering epithelial damage (graded 0-3, normal to severe), inflammatory cells infiltration (from 0 to 4, absence to severe involving submucosa), separation of muscle layer and muscularis mucosae (from 0 to 2, normal to severe) and goblet cell depletion (0-4, absent to present). Freiburg, Germany). To determine the level of non-specific staining, the preparations were incubated without the primary antibody.
| Compoundsanddrugs
Barium 
| Statisticalanalysis

| RESULTS
As shown in Fig. 1 , 5-FU significantly reduced bodyweight gain and food intake, but it did not significantly modify water intake. WIN alone did not significantly modify any of those parameters, and did not further significantly alter the values obtained in 5-FU treated rats.
| Gastrointestinalmotilitystudy
Compared to control animals, 5-FU (1st dose, 150 mg kg
) delayed gastric emptying on day 1, the difference being significant 6 and 8 hours after contrast. No significant alterations of the motility curves were observed for small intestine, caecum or colorectum ( Fig. 2A) . , two consecutive days, starting on day 1, ip, cumulative dose of 300 mg kg −1 ) or saline (2.5 mL). Thus, the following four groups were used: Veh+Saline (control, n=8); Veh+5-FU (n=12); WIN+Saline (n=4); WIN+5-FU (n=8). Bodyweight gain (A), food intake (B) and water intake (C) were recorded at the end of the four experimental days. Data represent mean±SEM. *P<.05, ***P<.001 vs control (one-way ANOVA followed by post hoc Bonferroni multiple comparison test) These results were confirmed also in the morphometric analysis for the stomach and caecum (Fig. 2B) . WIN (at 0.5 mg kg −1 , which in the invasive study was effective to reduce upper gastrointestinal transit, see Fig. S2 ) did not significantly alter any of these parameters in control or 5-FU-treated animals. The only exception was that in WIN+5-FU-treated animals the stomach size remained practically unaltered from 0 to 8 hours after contrast, whereas in vehicle+5-FU-treated rats the stomach size decreased a bit, the difference between these groups being statistically significant at T4 ( Fig. 2A and B) . Representative images of the different treatments, taken 8 hours after barium, can be seen in Fig. 2C .
On experimental day 4 (2 days after the 2nd dose of 5-FU, cumulative dose 300 mg kg −1 ), not only gastric motility, but also small intestinal and colorectal motility were altered by the antineoplastic drug. Thus, in 5-FU-treated rats, gastric emptying was significantly delayed, emptying of small intestine was significantly slower and motility in colorectum was also significantly delayed. WIN did not significantly modify these curves obtained with our semiquantitative score system either in saline-or 5-FU-treated rats (Fig. 3A) .
Interestingly, on day 4, the size of the stomach immediately after contrast was significantly lower than on day 1 in the groups of animals that received 5-FU (Fig. S3) . Throughout the experiment on ) or saline (2.5 mL). Thus, the following four groups were used: Veh+Saline (n=8); Veh+5-FU (n=12); WIN+Saline (n=4); WIN+5-FU (n=8). Twenty minutes after the first dose of 5-FU or saline, barium sulfate (2.5 mL, 2 g mL this day, the change in size of stomach and caecum was similar to that in control animals (Fig. 3B) . However, the caecum of the animals treated with 5-FU did not fill homogeneously with contrast: instead of spreading throughout the whole organ, barium accumulated in some area of it, and it was to some extent difficult to define the organ edges, compared to those in saline-treated rats, with or without WIN (Fig. 3C) . The quantitative analysis of the proportion of the organ intensely filled with barium showed that there was a significant decrease in this parameter in 5-FU-treated rats (Fig. 3B') . Once Finally, a further analysis was performed after realizing that on day 4 some barium contrast given on day 1 was still present in the small and large intestine of 5-FU-treated animals in X-rays taken immediately after contrast administration (T0) (Fig. 4B ).
This barium looked as "shadows" within each intestinal region and therefore we valued its presence and compared the results for the rats treated with vehicle+5-FU or with WIN+5-FU. As shown in Fig. 4B ', the presence of barium within the intestines of animals treated with WIN+5-FU was significantly higher than that remaining in animals treated with vehicle+5-FU. "Shadows"
were not found in any animal receiving vehicle+saline or vehicle+WIN (see a representative image of a saline-treated rat at T0
in Fig. 4B ). ) or saline (2.5 mL). Thus, the following four groups were used: Veh+Saline (n=8); Veh+5-FU (n=12); WIN+Saline (n=4); WIN+5-FU (n=8). On day 4 (2 days after the second dose of 5-FU or saline), 20 minutes after the fourth dose of WIN or vehicle, barium sulfate (2.5 mL, 2 g mL 
| Histopathologicalanalysis
The histological pattern in HE stained sections of the stomach is shown in Fig. S4A -D. Compared to control animals ( Fig. S4A) , damage was observed in the fundus area after 5-FU treatment ( ) or saline (2.5 mL). Thus, the following four groups were used: Veh+Saline (n=8); Veh+5-FU (n=12); WIN+Saline (n=4); WIN+5-FU (n=8). On day 1 (after the first dose of 5-FU) and 4 (2 days after the second dose of 5-FU or saline, 20 minutes after the fourth dose of WIN or vehicle), barium sulfate (2.5 mL, 2 g mL −1 ) was intragastrically administered and X-rays obtained 0-8 hours after contrast. A: Representative images of mild (upper panel) and severe (lower panel) diarrhea; in mild diarrhea the colon seems to contain both liquid and fecal pellets, whereas in severe diarrhea only liquid is seen in the colon. A': % of rats showing diarrhea (mild+severe, upper panel) or only severe diarrhea (lower panel) on the X-rays taken on experimental day 4; only 5-FU-treated animals were considered (none of saline-treated animals showed diarrhea on X-rays); data were statistically evaluated by means of χ 2 (although P>.05 in both cases, a tendency to a reduction in diarrhea, particularly severe diarrhea, was significantly decreased in 5-FU-treated animals ( Fig. 6A-B ). In contrast, the populations of goblet (Fig. 6C ) and enteroendocrine cells ( Regarding the non-mucosa components of the gut wall, submucosa thickness significantly increased in 5-FU-treated animals (Fig. 6E ). In the same way, muscle layer thickness also increased with 5-FU treatment both in the circular (Fig. 6F ) and the longitudinal layers (Fig. 6G) .
Immunohistochemistry with Ki67 antibody to detect proliferating cells confirmed the damage caused by 5-FU (Fig. S6A-D) . WIN treatment did not exert any significant effect on ileum structure, neither alone nor in combination with 5-FU (Fig. 6 ).
The histological structure of the colon is shown in Fig. 7A -E.
Damage was clear after treatment with 5-FU (Fig. 7B ) and 5-FU+WIN (Fig. 7D) ; ulcers and damage in mucosal architecture were evident ( Fig. 7B and D) , and large Peyer′s patches were also clearly seen (not shown). Both elements, namely mucosa damage and lymphatic nodules proliferation, contributed to the detrimental effect caused by 5-FU shown in the quantitative analysis (Fig. 7E) .
Finally, an immunohistochemical study of the presence of activated macrophages (using anti-CD163 antibody) was performed in both ileum and colon. As seen in Fig. 8 , macrophage infiltration significantly increased after 5-FU treatment in ileum (but not colon), and WIN did not significantly modify the results obtained in saline-or 5-FU-treated rats.
| DISCUSSION
Here, we asked if cannabinoids might be useful to prevent the development of CID. For this study, in rats, we used the antineoplastic drug 5-FU, and the non-selective cannabinoid agonist WIN, at a non-psychoactive dose. Besides weight gain loss and food intake reduction, 5-FU induced gastrointestinal dysmotility and diarrhea, which could be observed in vivo by radiographic means, and mucositis and other changes in gut wall 
| Generalhealthparameters
In agreement with other studies in experimental animals, 5-FU reduced bodyweight and food intake. 34, 39 This may be explained by the concomitant reduction in food intake, but other factors could also contribute. An increase in energy expenditure does not seem likely to be involved, because chemotherapy usually induces fatigue and reduces locomotor activity. 40, 41 In addition, tissues involved in metabolic use of the nutrients absorbed, such as the liver, might be affected by chemotherapy, 42 although these possibilities were not specifically addressed here. In contrast, we observed diarrhea, which may favor malnutrition and dehydration, contributing to weight gain reduction. Dehydration might have triggered an increase in water intake, but this parameter did not significantly change. The occurrence 
| Effectsonthestomach
In our radiographic analysis, the first dose of 5-FU delayed gastric emptying. This might be related to nausea and emesis occurring during 5-FU chemotherapy. 4, 6 Although apoptosis, the first process in mucositis development, occurred in the crypts from mouse ileum only 6 hours after 5-FU, 43 gastric dysmotility at this time-point was probably not due to established mucositis, which requires more time to occur. Cisplatin-induced nausea and emesis (and gastric dysmotility and distension), involve serotonin release from enterochromaffin cells, 44 and thus these effects are sensitive to 5-HT 3 antagonists. 45, 46 Delayed gastric emptying observed here 6-8 hours after 5-FU might as well involve serotonin release, as plasma serotonin was significantly increased 24 hours after the administration of a dose of 50 mg kg −1 5-FU in mice, 47 although, in contrast with cisplatin, maybe as a response to the production of inflammatory cytokines. 48, 49 On experimental day 4 (2 days after the second 5-FU administration), delayed gastric emptying was more apparent, although this did not involve gastric distension. Gastric dysmotility on day 4 might reflect the toxic consequences of 5-FU administration. Soares et al. promoted changes in the cellular and nuclear morphology. 50 Possibly other components of the gastric wall, which was damaged by 5-FU treatment both in fundus and body (see Fig. S4 ), or its extrinsic innervation, may also be altered, as has been shown for isolated gastric preparations from cisplatin-treated patients.
51
WIN had little effect on gastric motor function, either in control or 5-FU-treated animals, on day 1 or day 4. This was expected as low WIN doses, devoid of central effects (namely catalepsy), did not alter gastric emptying or size in previous radiographic studies. [19] [20] [21] 
| Effectsonthesmallandlargeintestine
The effects of 5-FU or WIN, alone or combined, on small or large intestinal motor function, were negligible on experimental day 1. Thus, 5-FU does not seem to induce any "acute" effect that may modify intestinal motor function in the few hours after its administration.
This was also found after the first dose of cisplatin. 28, 52, 53 WIN at 0.5 mg kg −1 significantly reduced upper gastrointestinal motor function in an invasive study (see Fig. S2 ), and tended to delay emptying of small intestine and arrival of barium to caecum and colorectum, as seen in previous studies.
19 -21 Gastrointestinal mucositis is most prominent in the small intestine, but occurs also elsewhere in the gut. 6 On day 4, typical features of mucositis were evident upon histological examination, including reduced villi height, reduced numbers of enterocytes/villus, and proliferating cells in the crypts, and increased infiltration of activated macrophages in ileum. 30, 54, 55 Radiographically, emptying of small intestine on day 4 was significantly delayed but arrival of barium to caecum (which may reflect small intestinal transit) was not. Upper gastrointestinal transit, invasively measured, 30 was altered 3 days after 5-FU (150 mg/kg), with delayed gastric emptying (see above), but accelerated small intestinal transit and duodenal hypercontractility (which was more intense after mucositis resolution) in organ bath studies. These effects may explain why arrival of barium to the caecum was not altered. Vacuolization and neutrophil infiltration 30 might have contributed to an increased thickness of the muscle layers in the small intestine (present study).
In addition to inflammation-related effects on the muscle (and maybe other motor components), direct actions of 5-FU on the smooth muscle cells 50 could also contribute to accelerated transit and small intestinal hypercontractility (present study 30 ).
Interestingly, in 5-FU-treated rats, barium did not distribute homogeneously within the caecum, and required much longer time to reach the colorectum. This uneven distribution of barium within the caecum may be due to fluid accumulation, excessively produced in the small intestine after 5-FU treatment. In fact, the rat caecum functions as a reservoir in conditions of small intestinal hypersecretion, and the cecectomized rat was suggested to be a good model of diarrhea. 56 Other factors including dysbiosis, already described in 5-FU-induced mucositis, 8, 57 and altered contractility, also likely in this intestinal organ, may have contributed to delayed arrival of barium to colorectum in 5-FU-treated rats. The contribution of all these factors will be specifically analyzed in future studies.
Once reached by barium, maximal filling of colorectum was much lower than in control animals. This may be due to the paucity of barium arrival, but also to the presence of diarrhea, which consequently interfered with adequate formation of fecal pellets and avoided barium to remain for a long time in this organ. Moderate to severe diarrhea was radiographically observable in 5-FU-treated animals, in similar proportions as previously found for similar doses in rats. 33 5-FU-induced diarrhea might reflect higher water content within the intestines, due to increased secretion and/or reduced absorption, associated to mucositis, but altered motor function might have also contributed. In fact, permanence within the intestines at T0 of barium administered on day 1 ("shadows") in 5-FU-treated rats (but not in saline-treated animals),
suggests the antineoplastic drug altered intestinal motor function even before day 4, at least in some animals. In vitro experiments in mice also suggest that contractility and peristalsis of colorectum are altered after 5-FU treatment. 58 In spite of the low, non-psychoactive dose of WIN used in this study, which did not alter gastrointestinal motor function per se and did not prevent most effects induced by 5-FU, including mucositis and macrophage infiltration, the cannabinoid reduced the incidence of diarrhea, particularly severe diarrhea, in 5-FU-treated animals.
Cannabinoids have been able to reduce diarrhea associated to many other inflammatory conditions of the colon, through activation of both CB 1 and CB 2 receptors. [22] [23] [24] [25] [26] Although clinical evidence is still lacking, it has already been suggested that the antidiarrheal cannabinoid effects might be useful during chemotherapy. 59 This is the first research addressing this possibility in experimental animals. Future work will ascertain the mechanisms involved.
The increased presence of "shadows" on day 4 from barium given on day 1 in animals treated with WIN+5-FU, compared to those treated with 5-FU only, suggests an antimotility effect of the cannabinoid, even at this low dose, which might be due to an increased expression of CB 1 receptor, as was found in other gut inflammation models, 60 whereas epithelial permeability might not be modified, at least not by a direct CB 2 -mediated mechanism. 27 More research is needed to determine the exact mechanisms of the possible antidiarrheal effect of cannabinoids in chemotherapy-treated animals.
| CONCLUDINGREMARKS
The effects of 5-FU on gastrointestinal motility have been characterized by radiographic means. Delayed gastric emptying, altered caecum motor function and diarrhea are present during the inflammatory phase of 5-FU toxicity (mucositis).
The cannabinoid agonist WIN, at a low dose, seemed to exert an antidiarrheal effect. New experiments will determine the receptor involved and whether other cannabinoid drugs, higher doses or other patterns of administration, alone or together with other drugs may be more useful to reach complete protection against diarrhea and, hopefully, against mucositis associated to chemotherapy.
